Evofem Biosciences: Q4 Earnings Insights


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Shares of Evofem Biosciences (NASDAQ:EVFM) decreased in after-market trading after the company reported Q4 results.

Quarterly Results

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Earnings per share were down 85.19% over the past year to ($0.50), which missed the estimate of ($0.36).

Revenue of $168,000 rose by 0.00% from the same period last year, which missed the estimate of $1,690,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Evofem Biosciences hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call


Want Private Access to Benzinga Analyst?

Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.


Date: Mar 04, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/zsc5tbs2

Price Action

Company's 52-week high was at $6.87

52-week low: $1.91

Price action over last quarter: Up 14.83%

Company Overview

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its focus is to advance the quality of life for women by developing solutions such as hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections. Its first commercial product, Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel, is for the prevention of pregnancy. Phexxi is hormone-free, female-controlled, on-demand prescription contraceptive gel. Its pipeline product candidate, EVO100, is being evaluated for the prevention of chlamydia and gonorrhea - two of the pervasive sexually transmitted diseases in the United States.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: EarningsBZI-Recaps